COMMUNIQUÉS West-GlobeNewswire

Press release: Terveystalo dental clinic network expands - Länsi-Vantaan Hammaslääkärit Oy to become a part of Terveystalo
05/02/2019
Terveystalo has signed an agreement to acquire Länsi-Vantaan Hammaslääkärit Oy, a private clinic that offers oral health services in Vantaa. The company's employees will be transferred to Terveystalo as old employees [...]
Announcement no. 1/2019 – Interim Financial Report, Q1 2018/19
05/02/2019
Q1 2018/19 Interim financial report, Q1 2018/19 (01 October 2018 - 31 December 2018) Solid start to the year, guidance for 2018/19 maintained Coloplast delivered 8% organic growth in the first quarter. Reported revenue [...]
Nu-Med Plus, Inc. Produces New, Smaller, and Smarter Inhaled Nitric Oxide Delivery Unit for Clinical Settings
05/02/2019
Nu-Med Plus’s inhaled nitric oxide clinical unit is designed to open new patient markets by providing in-office treatment options for conditions such as high blood pressure, COPD and ARDS SALT LAKE CITY, Feb. 05, 2019 ( [...]
NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL) - UPDATED VERSION
05/02/2019
THE SHAREHOLDERS OF OASMIA PHARMACEUTICAL AB (PUBL) ARE HEREBY GIVEN NOTICE OF THE EXTRAORDINARY GENERAL MEETING ON TUESDAY 19 MARCH 2019, AT 14.00 P.M., AT THE OFFICES OF THE COMPANY AT VALLONGATAN 1, 752 28 UPPSALA. [...]
NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL)
05/02/2019
THE SHAREHOLDERS OF OASMIA PHARMACEUTICAL AB (PUBL) ARE HEREBY GIVEN NOTICE OF THE EXTRAORDINARY GENERAL MEETING ON TUESDAY 19 MARCH 2019, AT 14.00 P.M., AT THE OFFICES OF THE COMPANY AT VALLONGATAN 1, 752 28 UPPSALA. [...]
Transactions in relation to share buyback program
05/02/2019
Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
LIDDS adds another Scandinavian clinic to the NZ-DTX-001 clinical trial
05/02/2019
UPPSALA, SWEDEN - LIDDS AB (publ) has received approval from the Danish Medicines Agency (DKMA) to conduct its Phase I NZ-DTX-001 clinical trial. The Danish study is in addition to the Phase I NZ-DTX-001 clinical trial [...]
Novo Nordisk files annual report with the SEC
05/02/2019
Bagsværd, Denmark, 5 February 2019 - Novo Nordisk A/S has filed its Annual Report 2018 on Form 20-F for the financial year 2018 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of [...]
CellaVision AB launches new product, CellaVision® DC-1, for small and mid-sized hematology laboratories
05/02/2019
The information was released for public disclosure on February 5, 2019, at 08:20. The CellaVision® DC-1 strengthens the company's global position and opens a new segment of the market comprising about 100,000 small and [...]
Ossur Hf : Annual Report 2018
05/02/2019
Announcement no. 8/2019 Annual Report 2018 5 February 2019 Össur's Annual Report 2018 has just been published and is available for download at the link below. Online version of the Annual Report 2018 is available at [...]
Ossur Hf : Interim report Q4 2018
05/02/2019
Announcement no. 7/2019 Interim report Q4 2018 5 February 2019 Highlights Sales growth of 12% in local currency in Q4 2018, organic sales growth of 4% and reported growth of 9%. Sales growth of 7% in local currency in [...]
Annual Report 2018 for H.Lundbeck A/S
05/02/2019
Annual Report 2018 for H.Lundbeck A/S Attachment ANNUALREPORT2018
Lundbeck realized 8% growth in revenue (local currencies) and 48% growth in EPS in 2018
05/02/2019
Financial report for the period 1 January to 31 December 2018 Lundbeck realized 8% growth in revenue (local currencies) and 48% growth in EPS in 2018 HIGHLIGHTS Revenue reached DKK 18,117 million in 2018 representing an [...]
Neovacs to host KOL Meeting to discuss its therapeutic vaccin IFNalpha Kinoid for lupus treatment - February 11th Paris
05/02/2019
NEOVACS TO HOST KOL MEETING TO DISCUSS ITS THERAPEUTIC VACCINE IFN α KINOID FOR LUPUS TREATMENT FEBRUARY 11, 2019 – 17h00 Hôtel Renaissance Le Parc Trocadéro – Paris Paris and Boston, February 5 th 2019 – 7h30 CET - [...]
Néovacs organise une réunion KOL concernant son vaccin thérapeutique IFNalpha Kinoïde pour le traitement du lupus - 11 février à Paris
05/02/2019
NÉOVACS ORGANISE UNE RÉUNION KOL CONCERNANT SON VACCIN THÉRAPEUTIQUE IFNα KINOÏDE POUR LE TRAITEMENT DU LUPUS 11 FÉVRIER 2019 – 17h00 Hôtel Renaissance Le Parc Trocadéro - Paris Paris et Boston, le 5 février 2019 – 7h30 [...]
Sanofi : Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma
05/02/2019
Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma Study evaluated the benefit of isatuximab in combination with standard of [...]
Sanofi : L'essai de phase III consacré à l'isatuximab a atteint son critère d'évaluation principal de prolongation de la survie sans progression chez des patients atteints d'un myélome multiple ré...
05/02/2019
L'essai de phase III consacré à l'isatuximab a atteint son critère d'évaluation principal de prolongation de la survie sans progression chez des patients atteints d'un myélome multiple récidivant/réfractaire L'essai a [...]
Idorsia announces the first patient recruited into REACT - the Phase 3 registration study with clazosentan
05/02/2019
REACT assesses the efficacy and safety of intravenous clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia following aneurysmal subarachnoid hemorrhage (aSAH) On [...]
GENFIT: Reports Full-Year 2018 Financial Results: cash position of €207.2m as of 12.31.2018
05/02/2019
GENFIT: Reports Full-Year 2018 Financial Results: cash position of €207.2m as of 12.31.2018 GENFIT achieved significant development milestones in 2018: Completed enrollment of interim analysis cohort for phase 3 RESOLVE [...]

Pages